NewsRoom Articles - Page 180 of 198

TuesdaySep 29, 2020 12:37 pm

CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020 CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members,…

TuesdaySep 29, 2020 10:45 am

Researchers Develop Simple Way to Detect Coronavirus Antibodies Using Glucose Monitors

Three scientists from Johns Hopkins; a biomedical engineer, a pharmacologist and a biophysicist, have come together to build a device that can detect if an individual has SARS-CoV-2 antibodies, which is the virus that causes COVID-19. Antibodies are small proteins produced by the immune system to help your body counteract a viral encounter and provide the immunity to fight it off if future infections occur. The researchers derived their inspiration from a glucose monitor, which is used by millions of people around the world. This, they said, could help them design an antibody detector that can be used easily and…

MondaySep 28, 2020 2:45 pm

New AI Tool Can Quickly Spot Coronavirus Outbreaks in US Counties

Researchers from Georgia Tech, Harvard Medical School and the Boston Medical Center have developed a new online learning-based tool that allows the health sector to detect coronavirus outbreaks earlier in various counties in the U.S. The Coronavirus outbreak detection tool is usually updated 2-3 times every week. It forecasts how fast a coronavirus outbreak will spread in a county by approximating the doubling rate of cases. The doubling time refers to the total number of days it takes for the cases in any given county to double. The tool takes into consideration the reported coronavirus deaths and cases, social distancing…

MondaySep 28, 2020 10:45 am

Wearable Device May Help EMTs Evaluate Hemorrhaging and Save Lives

Medical technicians, room physicians and military medics may be better equipped to treat victims of gunshot wounds, battlefield injuries and vehicular accidents thanks to a new device that is in the works. The device can evaluate the effects of hemorrhage on an individual. The research team currently working on the device development have demonstrated that the device could accurately evaluate blood loss through the measurement of seismic vibrations in an individuals’ thoracic cavity and also by detecting the changes in an individual’s heartbeat. Associate professor in the School of Electrical and Computer Engineering at the Georgia Institute of Technology, Omer…

FridaySep 25, 2020 2:15 pm

Researchers Make Breakthrough Discovery That Could Transform Cancer Treatment

Recently, Professor Federica Sotgia and Professor Michael Lisanti made a discovery that could make cancer a treatable ailment. For many years, billions of dollars have been poured into the field of cancer research in an effort to find ways to treat and cure the disease. However, there are still no FDA/MHRA approved drugs that combat metastasis. As a result, cancer metastasis, which is lethal, remains an untreatable and mysterious disease. For those who may not be completely familiar with cancer metastasis; this is when cancer cells spread throughout the body’s organs such as the lungs, bone tissue, the brain and…

FridaySep 25, 2020 1:15 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Industry reports estimate that the global brain…

FridaySep 25, 2020 12:00 pm

Researchers Invent Tiny Robot to Change the Future of Surgery

Researchers from the Georgia Institute of Technology and Ohio State University have discovered a way to send soft tiny robots into humans. This may open the door for ways to deliver treatments for various conditions ranging from aortic artery blockages to colon polyps as well as less invasive surgical procedures. The comprehensive study, which uses origami, an ancient Japanese practice, was published in the Proceedings of the National Academy of Sciences on September 14. Renee Zhao, an assistant professor of mechanical and aerospace engineering at Ohio State University and the co-author of the paper, stated that using this method, doctors…

FridaySep 25, 2020 11:49 am

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States. 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020 Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most…

ThursdaySep 24, 2020 3:30 pm

Innovative Team Discovers N95 Masks Can Be Recharged to Restore Their Efficacy

Since the coronavirus crisis was declared a pandemic, N95 masks, which are a design of personal protective equipment have been in short supply. N95 masks as well as other masks used in the medical field use two filtration methods, electrostatic filtering and mechanical filtering using mask fibers. Electrostatic filtering uses stationary electric charges to attract and catch minute 0.3-micron particles such as fluid droplets that may contain viruses. N95 masks are also only for single day use as they become less effective at filtering out minute particles once the electrostatic charges that are present in the mask leak into the…

ThursdaySep 24, 2020 2:08 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal

POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since being acquired by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The contract calls for Soluble Biotech’s expertise in protein expression and solubility studies. “Our first…